AHL Partners’s Array Biopharma Inc ARRY Stock Holding History

AHL Partners’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-71,293	Closed	-$876K	–	1422
2017 Q3	$876K	Buy	+71,293	New	+$662K	0.02%	912

Other funds holding ARRY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AHL Partners's ARRY Position: Q4 2017 in Review

AHL Partners sold out of Array Biopharma Inc (ARRY) in Q4 2017, closing a stake of 71,293 shares — an estimated $876K sold.

AHL Partners first reported a position in ARRY in Q3 2017 and held it in 1 quarter. The position peaked at $876K in Q3 2017. 191 funds tracked by Wall St. Rank hold ARRY as of Q4 2017.

AHL Partners reported no remaining Array Biopharma Inc position as of Q4 2017 after selling out during the quarter.
AHL Partners sold 71,293 Array Biopharma Inc shares in Q4 2017, an estimated $876K.
AHL Partners first reported a position in Array Biopharma Inc in Q3 2017 and held it in 1 quarter.
AHL Partners's Array Biopharma Inc position peaked at $876K in Q3 2017.
191 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.